World Heart Federation Roadmap for Heart Failure

Publication date: September 2019Source: Global Heart, Volume 14, Issue 3Author(s): João Pedro Ferreira, Sarah Kraus, Sharon Mitchell, Pablo Perel, Daniel Piñeiro, Ovidiu Chioncel, Roberto Colque, Rudolf de Boer, Juan Esteban Gomez-Mesa, Hugo Grancelli, Carolyn S.P. Lam, Antoni Martinez-Rubio, John J.V. McMurray, Alexandre Mebazaa, Gurusher Panjrath, Ileana L. Piña, Mahmoud Sani, David Sim, Mary Walsh, Clyde Yancy
Source: Global Heart - Category: Cardiology Source Type: research

Related Links:

No abstract available
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Letters to the Editor Source Type: research
On the heels of the DAPA-HF outcomes trial, DEFINE-HF shows adding the SGLT-2 inhibitor to standard meds improved other endpoints heart failure patients care about, whether or not they had diabetes.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
Publication date: Available online 17 September 2019Source: The Annals of Thoracic SurgeryAuthor(s): Valentino Bianco, Arman Kilic, Thomas G. Gleason, Edgar Aranda-Michel, Yisi Wang, Forozan Navid, Ibrahim SultanAbstractBackgroundAn increase in the life expectancy of the general population has led to heightened numbers of elderly patients in need of coronary artery bypass grafting (CABG). Surgical revascularization in octogenarians is becoming more commonplace and outcomes in this cohort continue to gain relevance.MethodsAll patients who underwent isolated CABG (n=7048) at the University of Pittsburgh Medical Center from 2...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
This study compares the outcome of post-lobectomy patients in relation to the analgesic method used: parenteral analgesia (PA) vs. PVB + PA, and provides justification for the routine use of PVB in all patients where CEA is contraindicated. METHODS: We randomized 213 consecutive patients undergoing open lobectomy to benefit from two different protocols of postoperative analgesia: PA vs. PVB +PA. We compared the frequency of cardiac hemodynamic, respiratory, pleural or surgical-related complications. RESULTS: After lobectomy, the PVB patients (72/213) were found to have a significantly lower frequency of congestive ...
Source: Annali Italiani di Chirurgia - Category: Surgery Tags: Ann Ital Chir Source Type: research
Conclusions: This study provides a strategy for understanding the mechanism of QLQX against CHF by combining pharmacokinetics study, network pharmacology, and experimental validation.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Ventrix, a spin-off company of the University of California San Diego, has developed a special hydrogel that can be injected into the heart to provide a platform for cardiac repair following a heart attack. The technology was just tested in humans fo...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Materials Source Type: blogs
Pulmonary hypertension, defined as a resting mean pulmonary artery pressure greater than or equal to 25 mmHg, results from a myriad of conditions. The Fifth World Symposium on Pulmonary Hypertension proposed a classification system that organizes pulmonary hypertension into five groups based on common hemodynamic, pathophysiologic, and therapeutic parameters.1 This review focuses on pulmonary arterial hypertension (Group 1 pulmonary hypertension), a disease in which progressive pulmonary vascular obstruction, remodeling, and destruction lead to increased right ventricular afterload and hypertrophy, right heart failure, and...
Source: Anesthesiology - Category: Anesthesiology Source Type: research
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 17, 2019 issue
Source: JAMA: This Week's Audio Commentary - Category: General Medicine Authors: Source Type: podcasts
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Conclusions After accounting for baseline PA, greater positive changes in leisure-time PA levels were associated with a more eccentric-type of LV remodeling pattern over 10 yr. The clinical implications of such findings remain to be determined.
Source: Medicine and Science in Sports and Exercise - Category: Sports Medicine Tags: EPIDEMIOLOGY Source Type: research
More News: Cardiology | Heart | Heart Failure